R
Ravithat Putvatana
Researcher at University of Hawaii at Manoa
Publications - 6
Citations - 352
Ravithat Putvatana is an academic researcher from University of Hawaii at Manoa. The author has contributed to research in topics: Serial passage & Virus. The author has an hindex of 6, co-authored 6 publications receiving 344 citations.
Papers
More filters
Journal ArticleDOI
Haiti: absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission.
Scott B. Halstead,Thomas G. Streit,Jack Guy Lafontant,Ravithat Putvatana,Kevin L. Russell,Wellington Sun,Niranjan Kanesa-thasan,Curtis G. Hayes,Douglas M. Watts +8 more
TL;DR: Dengue transmission rates were studied in school children in Carrefour Borough, Port-au-Prince, Haiti and observations, which are reminiscent of those in Africa, provide further evidence of a dengue resistance gene in black populations.
Journal ArticleDOI
Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. III. Reversion to virulence by passage of cloned virus in fetal rhesus lung cells.
Scott B. Halstead,Nyven J. Marchette,Arwin R. Diwan,Nicholas E. Palumbo,Ravithat Putvatana,Linda K. Larsen +5 more
TL;DR: Two strains of primary dog kidney-passaged dengue (DEN) 4 (H-241) virus cloned by terminal dilution were propagated in fetal rhesus lung (FRhL) cells to produce candidate vaccine virus seeds and PDK 35-TD3 is a promising candidate for trial in man.
Journal ArticleDOI
Immunogenicity of Live Attenuated SA14-14-2 Japanese Encephalitis Vaccine—A Comparison of 1- and 3-Month Immunization Schedules
Theodore F. Tsai,Yu YongXin,Jia Li Li,Ravithat Putvatana,Zhang Ran,Wang Shougui,Scott B. Halstead +6 more
TL;DR: The routine administration of JE SA14-14-2 vaccine to infants in an EPI schedule should be possible using either interval, and mean titers were almost 2-fold higher with the longer schedule.
Journal ArticleDOI
Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. IV. Characterization of a vaccine candidate in fetal rhesus lung cells.
TL;DR: Because of its safety and desirable monkey virulence attributes PDK 35-TD3 FRhL p3 is recommended for human phase I trial.
Journal ArticleDOI
Absence of dengue 2 infection enhancement in human sera containing Japanese encephalitis antibodies.
TL;DR: The failure of human anti- JE contrasts with the ability of rabbit anti-JE to enhance DEN-2 infections, but correlates with the absence of recorded instances of dengue shock syndrome in human beings sequentially infected with JE and then a DEN virus.